Companies › Clarity Pharmaceuticals
2 active drug programs in 4 registered trials: 2 Phase 3, 2 Phase 1; Oncology; next expected readout Dec 2026.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| 64Cu-SAR-bisPSMA 64Cu-labeled anti-PSMA bisPSMA antibody for imaging | PSMA, FOLH1 | Phase 3 | Prostate Cancer; Prostatic Neoplasms, Castration-Resistant | Dec 2026 |
| 67Cu-SAR-bisPSMA 67Cu-labeled anti-PSMA bisPSMA antibody for therapeutic targeting | PSMA | Phase 1 | Prostatic Neoplasms, Castration-Resistant | – |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT06056830 | 64Cu-SAR-bisPSMA | Phase 3 | Prostate Cancer | Oncology | Sep 2026 |
| NCT04868604 | 64Cu-SAR-bisPSMA | Phase 1 | Prostatic Neoplasms, Castration-Resistant | Oncology | Sep 2026 |
| NCT04868604 | 67Cu-SAR-bisPSMA | Phase 1 | Prostatic Neoplasms, Castration-Resistant | Oncology | Sep 2026 |
| NCT06970847 | 64Cu-SAR-bisPSMA | Phase 3 | Prostate Cancer | Oncology | Dec 2026 |
Fusion Pharmaceuticals Curium US Norroy Bioscience Lantheus Medical Imaging ABX advanced biochemical compounds
Pipelines of the same shape: areas, drug types, target families, stage and cash runway.
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.